Banning Misleading Drug Ads Act of 2022

Hozzl · 2022-12-29T18:05:01Z

Explore the details of House Bill 8289 Banning Misleading Drug Ads Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 6:05 PM

Summary of Bill HR 8289

Bill 117 HR 8289, also known as the Banning Misleading Drug Ads Act of 2022, is a piece of legislation introduced in the US Congress with the aim of addressing the issue of misleading advertisements for pharmaceutical drugs. The bill seeks to protect consumers from false or deceptive advertising practices by pharmaceutical companies.

The key provisions of the bill include:

1. Prohibiting pharmaceutical companies from making false or misleading claims about the safety or effectiveness of their drugs in advertisements. This includes claims that are not supported by scientific evidence or that exaggerate the benefits of the drug while downplaying potential risks. 2. Requiring pharmaceutical companies to provide accurate and balanced information about their drugs in advertisements, including information about potential side effects, contraindications, and limitations of use. 3. Establishing penalties for pharmaceutical companies that violate the provisions of the bill, including fines and potential criminal charges for egregious violations. 4. Providing the Federal Trade Commission (FTC) with the authority to enforce the provisions of the bill and investigate complaints of misleading drug advertisements. Overall, the Banning Misleading Drug Ads Act of 2022 aims to protect consumers from deceptive advertising practices in the pharmaceutical industry and ensure that they have access to accurate and reliable information about the drugs they are prescribed. The bill is currently under consideration in Congress and has garnered bipartisan support for its efforts to promote transparency and accountability in drug advertising.

Congressional Summary of HR 8289

Banning Misleading Drug Ads Act of 2022

This bill finalizes a 2010 proposed rule from the Food and Drug Administration (FDA) regarding television and radio prescription drug advertisements if the FDA does not otherwise issue a final rule within 180 days of the bill's enactment. (The proposed rule specifies standards for major statements about a drug's side effects in television and radio advertisements.)

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 8289

Bill HR 8289 is currently in the status of Bill Introduced since July 5, 2022. Bill HR 8289 was introduced during Congress 117 and was introduced to the House on July 5, 2022. Bill HR 8289's most recent activity was Referred to the House Committee on Energy and Commerce. as of July 5, 2022

Bipartisan Support of Bill HR 8289

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 8289

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 8289

Banning Misleading Drug Ads Act of 2022

To require the Secretary of Health and Human Services to promulgate a past due final rule with respect to direct-to-consumer prescription drug advertisements, and for other purposes.